|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||32.58|
Insider Roundup While analyst recommendations can be a hit or miss, insider transactions are usually more telling of a company’s future stock behavior. Insiders are major owners and/or management of a ...
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Park Lane Advisor has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Dyax Corporation ...
For the S&P 500, 2016 cannot be described as anything less than a bloodbath to this point. The market hit new 52-week lows once again on Wednesday, but incredibly there are a handful of stocks making new ...